Among adults receiving legally prescribed or dispensed buprenorphine or methadone, extra-medical use of these same medications was reported at one in every 10 visits.
Searching for Solutions
In this clinical trial, CBT and PRS had no effect on rates of opioid abstinence in the year following the initiation of MOUD.
Findings illuminate points of intervention for alternative approaches to discipline that minimize harm among school-aged youth.
Transgender youth access to health care that is inclusive, gender-affirming, and evidence-based is recommended in AAPP’s newest policy statement along with opposition to “conversion” or “reparative” treatment models which are ineffective, deceptive, and lack in evidence.
In its newest policy statement, AAPP reaffirms support to transgender youth access to health care that is inclusive, gender-affirming, evidence-based, and developmentally appropriate. The statement additionally opposes “conversion” or “reparative” treatment models as ineffective, deceptive, and lack in evidence. Please visit these evidence-based policy asks and use them as the basis for advocacy in your city, state, and federally.
Rescheduling cannabis and psychedelics is recommended by AAPP as means to reduce barriers to rigorous clinical research with the goal to strengthen the evidence base on both benefit and harm.
AAPP’s newest policy requests provide support to rescheduling cannabis and psychedelics to reduce barriers to rigorous clinical research with the goal to strengthen the evidence base on both benefit and harm. Please visit these policy asks and use them as the basis for advocacy in your city, state, and federally.
Gambling disorder and problem gambling research and treatment are needed and supported by AAPP given the limited research on screening and treatment of gambling disorder.
The FDA reversed years of strict enforcement against flavored vapes by authorizing the first legal fruit-flavored e-cigarettes for adults over 21. AAPP supports policies that reduce access to products such as flavored vapes that are attractive to youth.
AAPP has released requests related to implementation of federal policies that reduce access to nicotine-containing products among teens and adolescents including flavored vaping products that increase youth appeal. Additionally, with increased incidence of gambling disorder and problem gambling, AAPP has issued support for increased research into and access to treatment given that there are currently no FDA-approved medications for treatment of gambling disorder.
The AAPP Board has approved several timely policy asks focused on the evidence and in support of our federal advocacy on behalf of you as members and the patients we serve. Members are encouraged to review these policy asks and use as you conduct your own advocacy efforts at the local, state, and federal level.
AAPP's newest member toolkits address “gas station drugs” including tianeptine and phenibut. Clinical presentation, pearls and management of acute intoxication and withdrawal are among the topics included.
Authored by Sarah Thomason, PharmD, BCACP, BCPP, FAAPP, AAPP has released two new toolkits to help clinicians address the growing issue of “gas station drugs”—unregulated substances commonly sold in convenience stores. These resources address tianeptine and phenibut as emerging drugs linked to risks such as dependence, withdrawal, and serious adverse effects. Clinical presentation, diagnostic approach, and management of acute intoxication and withdrawal are among the topics included.
Deprescribing of psychotropics should be done in an evidence-based and personalized way per AAPP's newest policy brief. Psychiatric pharmacists are well-equipped to distinguish the risks and benefits of deprescribing and/or the need for long-term psychotropic treatment.
This policy brief supports and describes an evidence-based and personalized approach to psychotropic deprescribing. The brief additionally outlines that additional research is needed to determine tapering protocols and emphasizes the importance of recognizing that many individuals will still benefit from long-term psychotropic medication treatment. Access this new policy document and use it as a tool in your own advocacy surrounding this important issue.
Shared decision making is an essential element of mental health care and is supported by AAPP as a method to reduce stigma and contribute to improved quality of life.
This policy brief supports the use of shared decision making (SDM) by all health care providers as an essential element of the patient care process for all individuals living with a mental health condition. Access this new policy document and use it as a tool in your own advocacy surrounding this important issue.
This study examined purity of fentanyl samples and estimated the typical daily oral milligrams of morphine equivalent (MME).
As I write my first presidential column, I find myself reflecting on the journey that brought me to this role—the patients during my APPE at the San Antonio State Hospital who opened my eyes to why psychiatric pharmacy matters, the mentors who challenged and inspired me as a student, resident, and throughout my career, and the dedicated volunteers and staff who make AAPP's work possible.
These results add to a growing body of evidence that CB1 neutral antagonists can attenuate the rewarding properties of opioids while sparing their therapeutically desirable antinociceptive effects, providing support for further investigation of CB1 neutral antagonists as possible treatments for OUD.
In this study estimating the effects of reducing federal funding for SSPs, the findings suggest that mortality will increase among persons who inject drugs during the 5 years after loss of funding.
Psychotherapy, including cognitive behavior therapy and motivational interviewing, offers short-term benefits; however, its long-term effectiveness is uncertain.
Adults with CUD seem to receive less stigma compared to adolescents with CUD, while stigmatizing attributions are produced less often when people have more contact with cannabis use and CUD.
In this study of hospitalized adults with OUD, treatment of opioid withdrawal with short-acting opioids exhibited a dose-dependent association with reduced hazard of early patient-directed discharge.
Very low certainty evidence suggests that, among people with opioid use disorder who have undergone withdrawal and wish to remain abstinent, a substantial percentage are willing to initiate naltrexone with marked early discontinuation.